NSD1 and neoplasm: Immune checkpoint inhibitors are showing great promise in numerous tumor types; however, HNSCC tumors with inactivating NSD1 mutations have an “immune cold” microenvironment, characterized by the reduced infiltration by tumor-associated leukocytes (18).